MCF7/164R-1 Cell Line

The MCF7/164R-1 Cell line is a breast cancer cell line resistant to fulvestrant. Treatment with the steroidal antiestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance.

Contributors

Inventor Institute
Anne Lykkesfeldt Danish Cancer Society
SKU: 152091
Product description: The MCF7/164R-1 Cell line is a breast cancer cell line resistant to fulvestrant. Treatment with the steroidal antiestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance.
Production details: The MCF7/164R-1 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 164,384 in 100 nM concentration, see Lykkesfeldt et al 1995. The MCF7/164R-1 cells are also resistant to the pure steroidal antiestrogen fulvestrant (ICI 182,780) and can be maintained continuously in growth medium with 100 nM fulvestrant.
Additional notes: Upon withdrawal of fulvestrant, the cells express ER alpha, although at a reduced level compared to the parental MCF7/S0.5 cell line. The MCF7/164R-1 cells do not express progesterone receptor. The MCF7/164R-1 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells.
Cellosaurus ID: CVCL_1D48
Parental cell line: MCF7 S0.5
Disease: Cancer
Cat. #: 152091
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Breast cancer
Research Fields: Cancer;Drug development
Organism: Human
Tissue: Breast
Model: Tumour line
Cancer Types In Detail: Breast cancer;Fulvestrant resistant
Format: Frozen
Shipping conditions: Dry ice
Growth medium: Phenol red free DMEM/F12 (1:1) supplemented with 1% FCS, Glutamax 2.5 mM and 6 ng/ml insulin. Supplemented with 100nM fulvestrant to maintain resistance.
References:

Thrane et al. 2015. Oncogene. 34(32):4199-210. PMID: 25362855.

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Sonne-Hansen et al. 2010. Breast Cancer Res Treat. 121(3):601-13. PMID: 19697122.

Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.

Frogne et al. 2009. Breast Cancer…

Related Tools for Cell lines

Cat. # Tool Name
151665 MEF PKCe KO Cell Line Key Info View Tool
151449 JIM1 Cell Line Key Info View Tool
151480 HEK293A EGFP-LC3 Cell Line Key Info View Tool
151503 1-7 CE1 Cell Line Key Info View Tool
151576 MEF RAF1 KO Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.